Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Vaccines

Free Subscription 17.11.2025 1 Ann Intern Med 1 Arch Virol 1 BMC Pediatr 1 BMJ 1 Clin Infect Dis 1 J Pediatr 4 J Virol 1 JAMA 1 Lancet 1 Nat Med 1 Pediatrics 3 PLoS One 1 Proc Natl Acad Sci U S A 1 Science 28 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. SHABBIR R, Shabbir Z
   A Reminder in Every Story: The Cost of Vaccine Hesitancy.
   Ann Intern Med. 2025 Nov 11. doi: 10.7326/ANNALS-25-02508.
   PubMed        
   
   

   
   Arch Virol

2. HUSSEIN NA, Azouz RAM, El-Shenawy R, Helmy NM, et al
   A virus-like-particle-producing DNA vaccine triggers specific humoral immunity against hepatitis C virus in mice.
   Arch Virol. 2025;170:244.
   PubMed        
   
   

   
   BMC Pediatr

3. YANG M, Wang Y, Gao J, Yao C, et al
   Impact of SARS-CoV-2 variants and vaccination on pediatric febrile seizures: a retrospective cohort study.
   BMC Pediatr. 2025;25:929.
   PubMed        
   
   

   
   BMJ

4. EPEE-BOUNYA A
   Maintain vaccine mandates to save children's lives.
   BMJ. 2025;391:r2386.
   PubMed        
   
   

   
   Clin Infect Dis

5. SCOTT PT, Pathirana J, Kato A, Tytus R, et al
   A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naive Adults 18-64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE
   Clin Infect Dis. 2025 Nov 10:ciaf604. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Pediatr

6. PETTOELLO-MANTOVANI M, Haddad J, Kuli-Lito G, Giardino I, et al
   From Misinformation to Action: A Multi-Faceted Approach to Combating Vaccine Hesitancy.
   J Pediatr. 2025 Nov 5:114895. doi: 10.1016/j.jpeds.2025.114895.
   PubMed        
   
   

   
   J Virol

7. JAMIESON PJ, Shen X, Abu-Shmais AA, Wasdin PT, et al
   Glycan-reactive antibodies isolated from human HIV-1 vaccine trial participants show broad pathogen cross-reactivity.
   J Virol. 2025 Nov 10:e0125625. doi: 10.1128/jvi.01256.
   PubMed         Abstract available
   
   
8. WEI X-F, Zhao L, Zhao Z, Gong Y-M, et al
   Design of antibody structure-guided epitope vaccines in silico to induce potent immune responses against emerging viruses.
   J Virol. 2025 Nov 11:e0068925. doi: 10.1128/jvi.00689.
   PubMed         Abstract available
   
   
9. NAITO T, Ushirogawa H, Kunishio M, Yano H, et al
   Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant.
   J Virol. 2025 Nov 13:e0139025. doi: 10.1128/jvi.01390.
   PubMed         Abstract available
   
   
10. YAN W, Liu X, Jiang S, Li H, et al
    Emergence and characterization of historically extinct virulent genotype IV Newcastle disease virus in wild and domestic birds: genetic insights, pathogenicity, and vaccine efficacy.
    J Virol. 2025 Nov 13:e0164625. doi: 10.1128/jvi.01646.
    PubMed         Abstract available
    
    

    
    JAMA

11. FRIEDEN TR, Schaffner W, Sharfstein JM
    CDC's Failure to Recommend COVID-19 Vaccination-"Shared Clinical Decision-Making" Is Abdication of Responsibility.
    JAMA. 2025 Nov 13. doi: 10.1001/jama.2025.22473.
    PubMed        
    
    

    
    Lancet

12. DE SANTIS M, Palou Redorta J, Nishiyama H, Krawczynski M, et al
    Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.
    Lancet. 2025 Oct 17:S0140-6736(25)01897-5. doi: 10.1016/S0140-6736(25)01897.
    PubMed         Abstract available
    
    

    
    Nat Med

13. RIBEIRO DOS SANTOS G, Jawed F, Mukandavire C, Deol A, et al
    Author Correction: Global burden of chikungunya virus infections and the potential benefit of vaccination campaigns.
    Nat Med. 2025 Nov 10. doi: 10.1038/s41591-025-04065.
    PubMed        
    
    

    
    Pediatrics

14. IRVING SA, Rowley EAK, Chickery S, Dascomb K, et al
    Effectiveness of 2023-2024 COVID-19 Vaccines in Children in the United States.
    Pediatrics. 2025 Nov 13:e2025073212. doi: 10.1542/peds.2025-073212.
    PubMed        
    
    

    
    PLoS One

15. FU K, Jackson DB, Testa A
    Adverse childhood experiences and COVID-19 vaccination uptake: Examining the intersection of sex and urban-rural residence.
    PLoS One. 2025;20:e0336390.
    PubMed         Abstract available
    
    
16. EZEZIKA O, Kotsaftis TS, Amponsah-Dacosta E, Demi S, et al
    Correction: A protocol for modeling the factors influencing the deployment of the COVID-19 vaccine across African countries.
    PLoS One. 2025;20:e0336507.
    PubMed         Abstract available
    
    
17. LU M, Bu Z, Xiang N, Yu J, et al
    Association between COVID-19 vaccination and atopic diseases in US adults: A retrospective cohort study.
    PLoS One. 2025;20:e0336698.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

18. BI K, Bandekar SR, Bouchnita A, Cramer A, et al
    Estimated impact of 2022-2023 influenza vaccines on annual hospital burden in the United States.
    Proc Natl Acad Sci U S A. 2025;122:e2505175122.
    PubMed         Abstract available
    
    

    
    Science

19. COHEN J
    The pandemic next time.
    Science. 2025;390:667-671.
    PubMed         Abstract available
    
    

    
    Vaccine

20. STOVRING H, Ekstrom CT, Schneider JW, Strom C, et al
    What is actually the emerging evidence about non-specific vaccine effects in randomized trials from the Bandim Health Project?
    Vaccine. 2025 Nov 13:127937. doi: 10.1016/j.vaccine.2025.127937.
    PubMed        
    
    
21. NAHAR N, Parveen S, Gurley ES, Ghosh PK, et al
    Community interpretation of a consent form and willingness to participate in a Nipah virus vaccine trial in Bangladesh.
    Vaccine. 2025;68:127953.
    PubMed         Abstract available
    
    
22. KUMAR P, Bateson D, Costa T, Ahmed S, et al
    HPV vaccination coverage and determinants in adolescent girls with disability: a scoping review.
    Vaccine. 2025;68:127968.
    PubMed         Abstract available
    
    
23. SAITO T, Couzinet A, Suzuki T, Shimomura M, et al
    Longitudinal monitoring of cellular immunity by the ex vivo activation of genes in leukocytes (EAGL) assay highlights potential markers of mRNA COVID-19 vaccine efficacy against breakthrough symptoms.
    Vaccine. 2025;68:127942.
    PubMed         Abstract available
    
    
24. KHUU E, Moussaoui S, Vignier N, Bonello K, et al
    Vaccine hesitancy among migrant populations in Europe: A mixed-methods systematic review.
    Vaccine. 2025;68:127954.
    PubMed         Abstract available
    
    
25. REEKIE J, Stepien S, Hendry A, Dalton L, et al
    Provider setting for influenza and COVID-19 vaccination among Australian adults in 2023 and 2024.
    Vaccine. 2025;68:127945.
    PubMed         Abstract available
    
    
26. ZHANG Q, Lewis KB, Phillips JC, Ma H, et al
    Decisional needs of older adults considering COVID-19 booster vaccinations: A systematic review comparing China with other countries.
    Vaccine. 2025;68:127949.
    PubMed         Abstract available
    
    
27. ZIDAN M, Trinh NTH, Desalegn A, Smith LH, et al
    BNT162b2 mRNA COVID-19 vaccine effectiveness in pregnancy: Emulating trial NCT04754594 using observational data from Norwegian health registries.
    Vaccine. 2025;68:127908.
    PubMed         Abstract available
    
    
28. CHENG C, Chen X, Ge Y, Sung MH, et al
    Assessing factors associated with one-year antibody waning in participants with repeated influenza vaccinations: A six-year cohort study.
    Vaccine. 2025;68:127904.
    PubMed         Abstract available
    
    
29. KAMATHEWATTA KI, Kanci Condello A, Ekanayake D, Noormohammadi AH, et al
    Day-old vaccination with the Vaxsafe MG304 live-attenuated vaccine protects chickens from tracheal transcriptional changes induced by chronic infection with Mycoplasma gallisepticum.
    Vaccine. 2025;68:127915.
    PubMed         Abstract available
    
    
30. CHEN G, Chen G, Wang S, Xing R, et al
    Modular design of a self-amplifying mRNA vaccine for multivalent immunization against Neisseria meningitidis B.
    Vaccine. 2025;68:127964.
    PubMed         Abstract available
    
    
31. O'BRIEN TL, Johnson DR
    U.S. state lawmaker support for COVID-19 vaccine policies during the pandemic.
    Vaccine. 2025;68:127930.
    PubMed         Abstract available
    
    
32. BICEGO A, Wood JG, Newall AT, Hogan AB, et al
    Effectiveness of maternal vaccines and long-acting monoclonal antibodies against respiratory syncytial virus disease burden in early life: a scoping review of dynamic modelling studies.
    Vaccine. 2025;68:127868.
    PubMed         Abstract available
    
    
33. MIRANDA-LOPEZ A, Castillo CG, Gonzalez-Ortega O, Romero-Maldonado A, et al
    The rpZDIII vaccine triggers vertical protection on newborn mice against zika virus infection.
    Vaccine. 2025;68:127941.
    PubMed         Abstract available
    
    
34. KOUZELI A, Hasan T, Smith K, Metelmann S, et al
    Impact of vaccination on shingles-related hospitalisations in 70-79-year-olds in Scotland between 2000 and 2023: A retrospective cohort study.
    Vaccine. 2025;68:127951.
    PubMed         Abstract available
    
    
35. REINHOLM A, Khan H, Laakso T, Maljanen S, et al
    Corrigendum to "Long-term neutralization capacity of vaccine and breakthrough infection induced SARS-CoV-2 specific antibodies against omicron subvariants BA.2, XBB.1.5, and JN.1" [Vaccine 68 (2025) 127894].
    Vaccine. 2025;68:127939.
    PubMed        
    
    
36. MCCARTHY K, Silkiss RZ
    Ocular manifestations of vaccine-preventable diseases: A comprehensive review.
    Vaccine. 2025;68:127900.
    PubMed         Abstract available
    
    
37. ZHU Y, Si M, Wang L, Zhang Y, et al
    Tolerability, safety, and preliminary immunogenicity assessment of different dosages of Quadrivalent inactivated influenza vaccine in healthy subjects aged 6-35 months: A single-center, dose-escalation, open-label phase I clinical trial.
    Vaccine. 2025;68:127962.
    PubMed         Abstract available
    
    
38. JEFFERY C, Cheyne CP, Buchan I, Garcia-Finana M, et al
    Effect of influenza vaccination on post-admission outcomes for influenza patients in England: a population-based cohort study.
    Vaccine. 2025;68:127933.
    PubMed         Abstract available
    
    
39. GARVEY K, Salmon DA, Dudley MZ, Brewer J, et al
    Associations between trust in public health, vaccine confidence, and COVID-19 vaccination among American adults.
    Vaccine. 2025;68:127955.
    PubMed         Abstract available
    
    
40. LAM LN, Berges A, Sedra A, Saengpet IS, et al
    A pentavalent vaccine targeting adhesins and metal-binding lipoproteins confers robust protection against enterococcal infections.
    Vaccine. 2025;69:127965.
    PubMed         Abstract available
    
    
41. LUHATA LUNGAYO C, Burnett E, Mulumba A, Milabyo A, et al
    Rotasiil vaccine effectiveness against rotavirus-associated hospitalizations in the Democratic Republic of the Congo: comparison of multivariate logistic regression and inverse probability treatment weighting methods in a test-negative design.
    Vaccine. 2025;68:127944.
    PubMed         Abstract available
    
    
42. DENG L, Fan X, Li J, Yin D, et al
    Characteristics of neuraminidase-specific immune responses in influenza vaccinated or naturally infected populations in Shenzhen, China.
    Vaccine. 2025;69:127918.
    PubMed         Abstract available
    
    
43. LEDDERER L, Nielsen KH, Skodborg L, Fage-Butler A, et al
    Public trust and mistrust of COVID-19 vaccines: A systematic meta-narrative review.
    Vaccine. 2025;69:127947.
    PubMed         Abstract available
    
    
44. FIORILLA C, Contarino F, Sorrentino M, Bella F, et al
    Socioeconomic deprivation and human papillomavirus vaccination inequities: evidence from Southern Italy.
    Vaccine. 2025;69:127986.
    PubMed         Abstract available
    
    
45. LAKSHMANASAMY R, Palaniraja S, Basu P
    "Beyond promises: Why India must act now to deliver HPV vaccination".
    Vaccine. 2025;69:127974.
    PubMed        
    
    
46. GRASSI CM, Feng J, Wahid R, Kandinov B, et al
    Immunogenicity and safety of a SARS-CoV-2 N-terminal domain and receptor-binding domain monovalent XBB.1.5 vaccine in Japanese participants.
    Vaccine. 2025;69:127960.
    PubMed         Abstract available
    
    
47. KANTOR J, Morrison M, Vanderslott S, Pollard AJ, et al
    Public attitudes towards intranasal and ultrasound mediated vaccine delivery: A cross-sectional study in the United Kingdom and United States.
    Vaccine. 2025;69:127950.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.